💊 #FDA Drug Approvals — September 2026
#Lirafugratinib, #Isembyld & #Zanvastro bring new approaches targeting FGFR, myostatin & RNA.

#Sevabertinib, #Camizestrant, #Imlunestrant, #Aqneursa & #Joenja expand therapeutic options across cancer, rare diseases & genetic disorders.

The FDA approved #imlunestrant + #abemaciclib for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer following progression on ≥1 line of endocrine therapy.
In the phase 3 EMBER-3 trial:
🔹Median PFS: 11.1 vs 5.5 months
🔹HR for progression/death: 0.53
🔹ORR: 35% vs 15%

#EliLilly's oral selective oestrogen receptor degrader (#SERD) #imlunestrant (Inluriyo), has received a second #FDA approval, this time in #combination with #CDK4/6 inhibitor #abemaciclib (Verzenio), another Lilly drug.

pharmaphorum.com/news/lily-ge...